Your browser doesn't support javascript.
loading
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
Shi, Yuankai; Cui, Jie; Zhou, Hui; Zhang, Xiaohong; Zou, Liqun; Cao, Junning; Gao, Yuhuan; Jin, Chuan; Li, Xiaoling; Liu, Hui; Peng, Zhigang; Xie, Liping; Zhang, Huilai; Zhang, Weihua; Zhang, Hongyu; Zhong, Liye; Zhou, Fang; Guo, Genny; He, Wenduo.
Afiliación
  • Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoy
  • Cui J; Department of Hematology, Gansu Provincial Cancer Hospital, Lanzhou, China.
  • Zhou H; Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, China.
  • Zhang X; Department of Hematology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
  • Zou L; Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Cao J; Department of Hematology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Gao Y; Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Jin C; Department of Medical Oncology, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China.
  • Li X; Department of Medical Oncology, Liaoning Cancer Hospital and Institute, Shenyang, China.
  • Liu H; Department of Hematology, Beijing Hospital, Beijing, China.
  • Peng Z; Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Xie L; Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhang H; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Zhang W; Department of Hematology, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, China.
  • Zhang H; Department of Oncology, The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, China.
  • Zhong L; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Zhou F; Department of Hematology, The 960th Hospital of the PLA Joint Logistics Support Force, Tai'an, China.
  • Guo G; Department of Medical Science, Genor Biopharma Co., Ltd., Shanghai, China.
  • He W; Department of Medical Science, Genor Biopharma Co., Ltd., Shanghai, China.
Cancer Immunol Immunother ; 72(9): 2991-3002, 2023 Sep.
Article en En | MEDLINE | ID: mdl-37289256
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Timo / Linfoma de Células B Grandes Difuso Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Timo / Linfoma de Células B Grandes Difuso Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article